CD30, TNF-receptor superfamily member, is a receptor for TNFSF8/CD30L. TRAF2 and TRAF5 can interact with this receptor and mediate the signal transduction that leads to the activation of NF-kappaB. This receptor is a positive regulator of apoptosis, and it also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. The CD30 antibody labels activated B and T cells. It has been useful in identifying Hodgkin’s lymphoma, anaplastic large cell lymphomas (ALCL) and primary cutaneous CD30+ T-cell lymphoproliferative disorders. In non-lymphoid malignancies, CD30 reactivity has been reported in embryonal carcinomas (ECs), seminomas, and hepatocellular carcinomas.
Clone
Ber-H2
Isotype
IgG1k
Host species
Mouse
Species Reactivity
Human
Cellular Localization
Membrane
Positive Control
Tonsil, Hodgkin’s lymphoma
Applications
IHC
Intended Use
Research Use Only
![CD30 (Ki-1 Antigen) [Ber-H2]](https://medaysis.com/wp-content/uploads/2022/08/CD30-Ber-H2-MC0314_human-Hodgkins-Lymphoma-1-e1735606223810.jpg)